Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy [5]

Annals of Hematology

Volumn 87, Issue 5, 2008, Pages 429-430

  Pettengell, R ^a   Schwenkglenks, M ^b   Bosly, A ^c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; LETTER; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BELGIUM; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; GREAT BRITAIN; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, NON-HODGKIN; MEDICAL AUDIT; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; VINCRISTINE;

EID: 41549152534     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0447-2     Document Type: Letter

References (6)

1. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433-2453
2. Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G; for the Lymphoma Dose Project: A National Study (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87:277-283
3. Marangolo M, Bengala C, Conte PF, Danova M, Pronzato P, Rosti G, Sagrada P (2006) Dose and outcome: The hurdle of neutropenia. Oncol Rep 16:233-248
4. Pettengell R, Bosly A, Bron D, Schwenkglenks M, Johnson P, Van Hoof A, Hancock B, De Brock R, Pagliuca A, Berneman Z, Thomas R, Ferrant A, Joyner M, Dauwe M, Verhoef G, Hoskin P (2006) Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Haematologica/Hematol J 91:69 (Abs 0185)
5. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M, The German High-Grade Non-Hodgkin's Lymphoma Study G (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641
6. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rube C, Loeffler M, The German High-Grade Non-Hodgkin's Lymphoma Study G (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633